Stocks to Watch in the Battle Against Fentanyl and Dangerous Drugs
Greenlane Holdings, Inc. (NASDAQ: GNLN) is entering the battle against dangerous drugs by launching a new line of fentanyl, xylazine, and drink spike detection test strips under the Safety Strips, Inc. brand. The products will be available for order starting September 25th through Greenlane's online retail platforms, with shipments beginning October 1st.
This initiative comes amid the growing opioid crisis in the United States, where drug overdose deaths have increased nearly six times since 2000, with opioids accounting for about 80,000 deaths in 2021. The rising incidence of drink spiking has also prompted legislative action, such as California's AB 1013, which mandates that certain establishments offer drug testing kits to patrons.
Greenlane's partnership with Safety Strips aims to provide affordable, easy-to-use solutions for detecting dangerous substances, leveraging Greenlane's extensive sales, marketing, and distribution network. The global opioid overdose treatment market is expected to reach $1.54 billion in 2024, with a projected CAGR of 7.2% through 2034.
Greenlane Holdings, Inc. (NASDAQ: GNLN) si sta inserendo nella lotta contro i farmaci pericolosi lanciando una nuova linea di strisce di rilevamento per fentanyl, xylazine e bevande adulterate con il marchio Safety Strips, Inc. I prodotti saranno disponibili per l'ordine a partire dal 25 settembre tramite le piattaforme di vendita online di Greenlane, con spedizioni che inizieranno il 1 ottobre.
Questa iniziativa arriva in un periodo di crescente crisi degli oppioidi negli Stati Uniti, dove le morti per overdose di droga sono aumentate di quasi sei volte dal 2000, con gli oppioidi responsabili di circa 80.000 morti nel 2021. L'aumento dei casi di bevande adulterate ha anche spinto all'azione legislativa, come l'AB 1013 in California, che impone a determinati stabilimenti di offrire kit di test per droghe ai clienti.
La partnership di Greenlane con Safety Strips mira a fornire soluzioni accessibili e facili da usare per il rilevamento di sostanze pericolose, sfruttando la vasta rete di vendita, marketing e distribuzione di Greenlane. Si prevede che il mercato globale del trattamento delle overdose da oppioidi raggiunga i 1,54 miliardi di dollari nel 2024, con un tasso di crescita annuale composto (CAGR) previsto del 7,2% fino al 2034.
Greenlane Holdings, Inc. (NASDAQ: GNLN) está ingresando en la batalla contra las drogas peligrosas lanzando una nueva línea de tiras de prueba para la detección de fentanilo, xylazine y bebidas adulteradas bajo la marca Safety Strips, Inc. Los productos estarán disponibles para pedir a partir del 25 de septiembre a través de las plataformas minoristas en línea de Greenlane, con envíos comenzando el 1 de octubre.
Esta iniciativa se produce en medio de la creciente crisis de opioides en los Estados Unidos, donde las muertes por sobredosis de drogas han aumentado casi seis veces desde el año 2000, con los opioides representando alrededor de 80,000 muertes en 2021. La creciente incidencia de adulteración de bebidas también ha provocado acciones legislativas, como la AB 1013 de California, que exige que ciertos establecimientos ofrezcan kits de prueba de drogas a los clientes.
La asociación de Greenlane con Safety Strips tiene como objetivo proporcionar soluciones asequibles y fáciles de usar para detectar sustancias peligrosas, aprovechando la extensa red de ventas, marketing y distribución de Greenlane. Se espera que el mercado global de tratamiento de sobredosis por opioides alcance los 1.54 mil millones de dólares en 2024, con una tasa de crecimiento anual compuesta (CAGR) proyectada del 7.2% hasta 2034.
Greenlane Holdings, Inc. (NASDAQ: GNLN)는 새로운 펜타닐, 자일라진 및 음료 스파이크 감지 시험 스트립 제품 라인을 Safety Strips, Inc. 브랜드로 출시하여 위험한 약물과의 전쟁에 나섭니다. 이 제품들은 9월 25일부터 Greenlane의 온라인 소매 플랫폼에서 주문할 수 있으며, 배송은 10월 1일부터 시작됩니다.
이번 이니셔티브는 미국에서 증가하는 오피오이드 위기 속에서 이루어지며, 2000년 이후 약물 과다복용 사망자가 거의 6배 증가했으며, 2021년에는 오피오이드로 인해 약 8만 명이 사망했습니다. 음료 스파이킹의 증가로 인해 캘리포니아의 AB 1013과 같이 특정 업소에서 고객에게 약물 테스트 키트를 제공하도록 의무화하는 법안도 등장했습니다.
Greenlane과 Safety Strips의 파트너십은 Greenlane의 광범위한 판매, 마케팅 및 유통 네트워크를 활용하여 위험한 물질을 감지하기 위한 저렴하고 사용하기 쉬운 솔루션을 제공하는 것을 목표로 합니다. 글로벌 오피오이드 과다복용 치료 시장은 2024년까지 15억 4천만 달러에 이를 것으로 예상되며, 2034년까지 7.2%의 연평균 성장률(CAGR)이 예상됩니다.
Greenlane Holdings, Inc. (NASDAQ: GNLN) entre dans la bataille contre les drogues dangereuses en lançant une nouvelle ligne de bandelettes de test pour la détection du fentanyl, du xylazine et des boissons altérées sous la marque Safety Strips, Inc. Les produits seront disponibles à la commande à partir du 25 septembre via les plateformes de vente en ligne de Greenlane, avec des expéditions commençant le 1er octobre.
Cette initiative intervient dans le contexte de la crise croissante des opioïdes aux États-Unis, où les décès par overdose de drogues ont augmenté presque six fois depuis 2000, les opioïdes représentant environ 80 000 décès en 2021. L'augmentation des cas d'altération de boissons a également incité à des actions législatives, comme la AB 1013 en Californie, qui oblige certains établissements à proposer des kits de test de drogues aux clients.
Le partenariat de Greenlane avec Safety Strips vise à fournir des solutions abordables et faciles à utiliser pour détecter des substances dangereuses, en tirant parti du vaste réseau de vente, de marketing et de distribution de Greenlane. Le marché mondial du traitement des overdoses d'opioïdes devrait atteindre 1,54 milliard de dollars en 2024, avec un taux de croissance annuel composé (CAGR) prévu de 7,2 % jusqu'en 2034.
Greenlane Holdings, Inc. (NASDAQ: GNLN) tritt den Kampf gegen gefährliche Drogen an und bringt eine neue Produktlinie mit Teststreifen zur Erkennung von Fentanyl, Xylazin und Getränkespiking unter der Marke Safety Strips, Inc. auf den Markt. Die Produkte sind ab dem 25. September über die Online-Verkaufsplattformen von Greenlane bestellbar, die Versand beginnt am 1. Oktober.
Diese Initiative kommt inmitten der wachsenden Opioidkrise in den Vereinigten Staaten, wo die Sterbefälle durch Drogenüberdosen seit 2000 fast um das Sechsfache gestiegen sind, wobei Opioide 2021 für etwa 80.000 Todesfälle verantwortlich waren. Die steigende Anzahl an Fällen von Getränkespiking hat auch zu gesetzlichen Maßnahmen geführt, wie etwa Kaliforniens AB 1013, die vorschreibt, dass bestimmte Einrichtungen Drogen-Testkits für die Kunden bereitstellen müssen.
Die Partnerschaft von Greenlane mit Safety Strips zielt darauf ab, kostengünstige, benutzerfreundliche Lösungen zur Erkennung gefährlicher Substanzen anzubieten und die umfangreiche Verkaufs-, Marketing- und Vertriebsnetz von Greenlane zu nutzen. Der globale Markt für die Behandlung von Opioidüberdosierungen wird voraussichtlich 2024 1,54 Milliarden Dollar erreichen, mit einer prognostizierten jährlichen Wachstumsrate (CAGR) von 7,2% bis 2034.
- Greenlane is launching a new line of drug detection test strips, expanding its product portfolio
- The company has secured exclusive distribution rights for Safety Strips in the US
- The global opioid overdose treatment market is projected to grow at a CAGR of 7.2% through 2034
- New legislation in California mandates the availability of drug testing kits, potentially increasing demand for Greenlane's products
- None.
Insights
The article highlights a significant market opportunity in the opioid overdose treatment sector, projected to reach
The partnership with Safety Strips and exclusive distribution rights in the US positions Greenlane to capitalize on this growing demand. Their established distribution network and brand partnerships provide a strong foundation for market penetration. The recent California legislation mandating drink spiking test kits in certain establishments further validates the market need and could lead to increased adoption across other states.
Greenlane Holdings' (NASDAQ: GNLN) move into the drug detection market diversifies its revenue streams beyond cannabis accessories. This strategic pivot could potentially offset challenges in the cannabis sector and tap into a more stable, growing market. The exclusive distribution agreement with Safety Strips provides a competitive edge.
Investors should note the potential for rapid revenue growth given the urgent need for these products and regulatory tailwinds. However, it's important to monitor the company's execution, particularly in marketing and distribution efficiency. The share repurchase program announced by Nutriband Inc., another player in this space, indicates confidence in the sector's future and could potentially signal similar moves by other companies targeting the opioid crisis market.
The introduction of easily accessible fentanyl and drink spike detection tests represents a significant step in harm reduction strategies. With over 106,000 drug overdose deaths in 2021, of which 80,000 involved opioids, these tests could play a important role in preventing fatalities. The integration of these tests into existing drug panels in hospitals, as seen with QuidelOrtho's ARK Fentanyl II Assay, could lead to more timely interventions.
However, it's important to note that while detection is crucial, it's only part of the solution. Comprehensive approaches including education, addiction treatment and policy changes are necessary. The Ready to Rescue initiative by Emergent BioSolutions, focusing on college communities, demonstrates the importance of targeted education and awareness campaigns in high-risk populations.
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - September 20, 2024) - Investorideas.com, a go-to investing platform covering cannabis stocks releases an industry snapshot looking at the battle against dangerous drugs, including fentanyl, featuring Greenlane Holdings, Inc. (NASDAQ: GNLN), one of the premier global sellers of premium cannabis accessories, child-resistant packaging, and specialty vaporization products.
Read the full article on Investorideas.com
https://www.investorideas.com/News/2024/biotech/09200Battle-against-Fentanyl-and-Dangerous-Drugs.asp
According to Fact.MR , "The global opioid overdose treatment market is expected to reach a value of US
Cannabis company Greenlane Holdings, Inc. (NASDAQ: GNLN) has entered the battle against dangerous drugs, but not only against opioids. Greenlane announced this week its plans to launch an all-new line of fentanyl, xylazine and drink spike detection test strips under the Safety Strips, Inc. brand of drug test strips. Products will be available to order beginning September 25th via the Company's multiple online retail storefronts, (vapor.com, puffitup.com, and higherstandards.com/) as well as its wholesale portal (wholesale.greenlane.com). Shipments will commence October 1st.
In August, Greenlane announced that it had entered into a non-binding letter of intent to be the exclusive distributor in the US of Safety Strips drug detection test strips. Greenlane has been a trusted partner for some of the most successful and well-known cannabis and lifestyle brands, such as Higher Standards, Marley Natural and K.Haring, providing full sales coverage, marketing, warehousing and logistics services.
"We are delighted to be working with the Safety Strips' team who share our high standards for safety and quality, and our strong focus on improving people's lives and enhancing their safety," said Barbara Sher, Chief Executive Officer for Greenlane. "By combining our extensive sales, marketing, and distribution network with Safety Strips ISO 13485 validated product line of easy, fast, and accurate test strips to detect the presence of various drugs, we can do our part to help prevent accidental overdoses as well as protecting individuals from drug-induced date rape."
The Opioid Epidemic in the United States
According to SHADAC.ORG, "Over the past two decades, the United States has experienced a growing crisis of substance abuse and addiction that is illustrated most starkly by the rise in deaths from drug overdoses. Since 2000, the annual number of overdose deaths from any kind of drug in the U.S. has multiplied nearly six times over, rising from 17,500 to over 106,000 people in 2021. The vast majority of these deaths (about 80,000) involved some form of opioids, including heroin, prescription painkillers, and, most prevalently in recent years, synthetic opioids such as fentanyl. Fentanyl and related synthetic opioids alone accounted for roughly 71,000 drug overdose deaths in 2021, and are also involved in most methamphetamine, cocaine, and prescription opioid overdose deaths-the next most common substances associated with overdose deaths."
The Rising Incidence of Drink Spiking
In a January 2023 article posted on Alcohol.org, it was reported that "According to the Office on Women's Health, date-rape drugs like Rohypnol, GHB, and ketamine are used because they are not easily detected, and victims often do not remember being drugged or assaulted until many hours later. In 2016, there were over 320,000 incidents of rape and sexual assault, and these incidents are often underreported for both women and men. According to RAINN, 11.2 percent of college students experience rape or sexual assault through force, violence, or incapacitation, and in terms of drug-facilitated sexual assault, alcohol is the No. 1 substance for assailants, next to prescription drugs with tranquilizing effects and Rohypnol, ketamine, GHB, and ecstasy."
In response to the rising prevalence of drink spiking, the Californian Assembly passed AB 1013, July 1, 2024. The bill mandates that approximately 2400 establishments with a Type 48 license, which allows the sale of beer, wine, and distilled spirits, must display signage informing patrons that drug testing kits are available.The new law requires businesses to display signs reading, "Don't get roofied! Drink spiking drug test kits are available here. Ask a staff member for details." Establishments must offer these drug testing devices either for sale or free of charge.
Additionally, news came out this week from Safe Supply Streaming Co Ltd. (CSE: SPLY) noting it has made significant progress within its portfolio through Safety Strips Inc. ("Safety Strips"), as they introduce high-performing, reliable test strips designed to combat the rising dangers of fentanyl, xylazine, and drink spiking.
This strategic initiative is expected to create substantial value for Safe Supply shareholders, as the demand for safety and drug testing continues to grow across North America. The product launch will enter the market through the recently announced US Expansion Agreement with Greenlane Holdings, Inc. (NASDAQ: GNLN).
High Performing and Reliable Testing:
Safety Strips' product launch provides consumers with an affordable, easy-to-use solution for detecting fentanyl and xylazine - two substances contributing to the escalating opioid crisis. In response to new California legislation, Safety Strips' Drink Spike Test strips meet the requirements of California Assembly Bill No. 1013, passed in July 2024, which mandates that bars and clubs offer drug testing kits to their patrons. The law is aimed at reducing incidents of drink spiking, a growing safety concern in the hospitality industry.
Safety Strips' detection products will be available for order starting September 25, 2024, across Greenlane's online retail platforms, with shipments commencing on October 1, 2024.
This week Nutriband Inc. announced a share repurchase program to buy back up to
From the news: Progress continues on the development of AVERSA Fentanyl, with the Company maintaining its target of submitting an NDA to the FDA in Q1/Q2 2025.
Nutriband Inc. is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Earlier this year, QuidelOrtho Corporation reported it has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a MicroTip® Partnership Assay ("MPA"). This Fentanyl assay will help hospital and emergency room customers respond to the critical demand for enhanced opioid testing, allowing on-site fentanyl testing in less than 10 minutes to aid in immediate clinical decisions.
From the news: According to the Centers for Disease Control and Prevention ("CDC"), the number of fatalities resulting from fentanyl overdoses has tripled from 2016 to 2021, with an ongoing upward trend. The CDC highlights California, Florida, New York, Pennsylvania and Ohio as states with the highest mortality rates attributed to fentanyl.1 Consequently, several states have responded by implementing regulations requiring fentanyl testing to be included as a required component of drugs-of-abuse test panels.
"This assay transforms laboratory efficiency by integrating fentanyl testing with existing protocols to eliminate the need for external screening tests, and consolidates a lab's drugs-of-abuse panel into a singular, streamlined system, reducing intervention time and ultimately helping to save lives," said Lily Li, Senior Director of Medical and Clinical Affairs at QuidelOrtho. "Our relentless commitment to diagnostics lies in empowering our customers with impactful assays, particularly those capable of delivering rapid drugs-of-abuse detection amidst the escalating opioid crisis."
From the news: Ninety percent of fentanyl is excreted as norfentanyl, which is a synthetic opioid and is not detected on standard drug screening. The ARK™ Fentanyl II Assay provides preliminary analytical test results by detecting this major metabolite, reducing the risk of false negatives. As part of QuidelOrtho's Vitros systems' menu of assays, the test offers clinical fentanyl testing for hospitals and emergency departments, providing an effective approach to preliminary urine drug testing.
From the news: Drug test results obtained in emergency departments play a crucial role in addressing unique hospital challenges. When patients test positive for opioids on a standard drug test, they're usually directed to drug treatment programs. However, these standard tests fail to identify synthetic opioids, such as fentanyl. Without specifically testing for fentanyl, instances of fentanyl exposure might be disregarded, potentially leading to missed opportunities for life-saving interventions like administering naloxone, an opioid overdose reversal medication.
Although the pharmaceutical played a key role in opioid addiction, companies in the sector are building out solutions.
Emergent BioSolutions Inc. announced last month, the kicking off the second year of the Ready to Rescue initiative, which will include new college football tailgate stops, in-stadium activities, Greek Life events and student wellness clinics. As part of these expanded efforts, pro football legend and campaign spokesperson, Emmitt Smith, will continue to share his story to raise awareness of opioid risks and inspire students, parents, faculty and alumni to be prepared to save a life with NARCAN® Nasal Spray, which is available over-the-counter (OTC).
From the news: The Centers for Disease Control and Prevention (CDC) recently announced a reduction in drug overdose deaths for the first time since 2018.1 However, opioid poisonings continue to be the leading cause of accidental death in the United States,2 with the highest rate of opioid misuse and dependency among those 18 to 25.3 What's more, research shows less than 15 percent of college students nationwide know how to administer naloxone,4 the active ingredient in NARCAN® Nasal Spray, which can reverse the effects of an opioid overdose, including those caused by fentanyl. Education on the dangers of fentanyl, the signs of an opioid poisoning and how to both access and administer NARCAN® Nasal Spray is vital to saving lives, particularly within college communities.
According to Yale Medicine, "Fentanyl isn't new; it has been used in the U.S. since 1960 as an intravenous anesthetic. It is still prescribed today by doctors, often in the form of patches and lozenges, for treating severe and chronic pain from cancer and other illnesses and injuries."
"But fentanyl has shifted from exclusively being produced by pharmaceutical companies to now also coming from drug cartels and other entities, says David Fiellin, MD, a Yale Medicine primary care physician who specializes in addiction medicine."
With news that the DEA proposed rules last month to reclassify cannabis from a schedule I to a schedule III substance, the shift can now really focus on dangerous drugs Greenlane Holdings, Inc. (NASDAQ: GNLN) has the built-in marketing, warehousing and logistics services to bring Safety Strips testing for dangerous substances to the market.
More info in Greenlane Holdings visit here
Research more cannabis stocks with Investor ideas free stock directory
https://www.investorideas.com/Marijuana-Stocks/Stocks_List.asp
About Investorideas.com - Big Investing Ideas
Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more.
Disclaimer/Disclosure: This news article featuring GNLN is a paid for news release on Investorideas.com. Our site does not make recommendations for purchases or sale of stocks, services or products. This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on X @investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800-665-0411
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223901
FAQ
When will Greenlane Holdings (GNLN) launch its new drug detection test strips?
What substances can Greenlane's (GNLN) new test strips detect?
How does Greenlane's (GNLN) partnership with Safety Strips benefit the company?
What is the projected market size for opioid overdose treatment in 2024?
